

Monia Marchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1251911/publications.pdf>

Version: 2024-02-01

128
papers

5,875
citations

87723

38
h-index

79541

73
g-index

130
all docs

130
docs citations

130
times ranked

7443
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
2	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	3.3	415
3	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	2.2	319
4	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. <i>Blood</i> , 2007, 110, 4030-4036.	0.6	233
5	Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2004, 89, 215-32.	1.7	199
6	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
7	Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2001, 98, 3249-3255.	0.6	197
8	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
9	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. <i>Haematologica</i> , 2008, 93, 741-752.	1.7	182
10	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. <i>Intensive Care Medicine</i> , 2013, 39, 2092-2106.	3.9	169
11	Proposed definition of "poor mobilizer"™ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. <i>Bone Marrow Transplantation</i> , 2012, 47, 342-351.	1.3	156
12	Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 424-431.	0.8	134
13	Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 625-633.	0.8	128
14	Consensus conference on the management of tumor lysis syndrome. <i>Haematologica</i> , 2008, 93, 1877-1885.	1.7	125
15	Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. <i>Leukemia Research</i> , 2010, 34, 1576-1588.	0.4	112
16	Chronic Myeloproliferative Disorders. Hematology American Society of Hematology Education Program, 2003, 2003, 200-224.	0.9	101
17	Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies. <i>Leukemia and Lymphoma</i> , 2002, 43, 2301-2307.	0.6	90
18	COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure. <i>Annals of Hematology</i> , 2020, 99, 1701-1707.	0.8	90

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2001, 114, 78-83.	1.2	85
20	Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2â€“Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia. <i>Journal of Clinical Oncology</i> , 2005, 23, 5688-5695.	0.8	81
21	Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. <i>British Journal of Cancer</i> , 1998, 78, 781-787.	2.9	75
22	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). <i>Blood</i> , 2005, 106, 2849-2853.	0.6	75
23	Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. <i>American Journal of Medicine</i> , 2001, 111, 130-139.	0.6	72
24	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	3.3	67
25	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2008, 93, 1364-1371.	1.7	66
26	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. <i>Haematologica</i> , 2009, 94, 550-565.	1.7	66
27	Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. <i>Blood</i> , 2018, 132, 547-550.	0.6	61
28	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. <i>Blood Cells, Molecules, and Diseases</i> , 2007, 38, 280-286.	0.6	60
29	Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. <i>Transfusion</i> , 2013, 53, 2340-2352.	0.8	59
30	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
31	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	1.2	56
32	Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis. <i>Clinical Drug Investigation</i> , 2014, 34, 9-17.	1.1	53
33	Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. <i>Transfusion</i> , 2012, 52, 893-905.	0.8	48
34	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). <i>Haematologica</i> , 2004, 89, 717-41.	1.7	48
35	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. <i>Lancet Haematology</i> , 2022, 9, e301-e311.	2.2	46
36	Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis: analyzing the decision in different clinical scenarios. <i>Journal of Internal Medicine</i> , 1998, 244, 217-226.	2.7	44

#	ARTICLE	IF	CITATIONS
37	Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2004, 124, 618-625.	1.2	43
38	Extended Anticoagulation for Prevention of Recurrent Venous Thromboembolism in Carriers of Factor V Leiden. <i>Thrombosis and Haemostasis</i> , 2000, 84, 752-757.	1.8	42
39	Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age. <i>Hum Vaccin</i> , 2007, 3, 14-22.	2.4	41
40	Deciding when to intervene: a Markov decision process approach. <i>International Journal of Medical Informatics</i> , 2000, 60, 237-253.	1.6	40
41	Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. <i>European Journal of Health Economics</i> , 2013, 14, 853-861.	1.4	40
42	Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. <i>Leukemia</i> , 2017, 31, 882-888.	3.3	40
43	Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 815-824.	0.7	39
44	HIF-1 α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	1.7	39
45	Cancer-related fatigue in Italian cancer patients: validation of the Italian version of the Brief Fatigue Inventory (BFI). <i>Supportive Care in Cancer</i> , 2013, 21, 413-419.	1.0	35
46	Identification of new BMP6 pro-peptide mutations in patients with iron overload. <i>American Journal of Hematology</i> , 2017, 92, 562-568.	2.0	35
47	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	2.0	34
48	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	0.6	33
49	SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 185-192.	2.0	32
50	Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 149-154.	1.0	32
51	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 75-85.	0.2	32
52	Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006, 91, 1662-73.	1.7	32
53	Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. <i>American Journal of Hematology</i> , 2018, 93, 698-703.	2.0	31
54	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30

#	ARTICLE	IF	CITATIONS
55	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	0.6	30
56	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2005, 90, 1236-57.	1.7	30
57	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006, 91, 96-103.	1.7	30
58	Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian national health service. <i>Clinical Therapeutics</i> , 2004, 26, 1546-1561.	1.1	28
59	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 875-888.	0.8	28
60	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. <i>European Journal of Haematology</i> , 2001, 66, 324-327.	1.1	26
61	Clinical and Economic Impact of Epoetins in Cancer Care. <i>Pharmacoeconomics</i> , 2004, 22, 1029-1045.	1.7	23
62	Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2009, 94, 102-112.	1.7	23
63	Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. <i>Annals of Oncology</i> , 2012, 23, 1825-1832.	0.6	22
64	The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2018, 182, 701-704.	1.2	22
65	Testing for Occult Cancer in Patients with Idiopathic Deep Vein Thrombosis – A Decision Analysis. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1319-1326.	1.8	21
66	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	0.6	18
67	A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 719-725.	1.3	17
68	What reimbursement for coronary revascularization with drug-eluting stents?. <i>European Journal of Health Economics</i> , 2004, 5, 309-316.	1.4	16
69	Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. <i>Internal and Emergency Medicine</i> , 2011, 6, 17-27.	1.0	16
70	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 221-235.	0.7	16
71	Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial. <i>Blood</i> , 2020, 136, 29-30.	0.6	16
72	Constitutional trisomy 8 mosaicism in primary myelofibrosis: relevance to clinical practice and warning for trisomy 8 studies. <i>Cancer Genetics and Cytogenetics</i> , 2007, 179, 79-81.	1.0	15

#	ARTICLE	IF	CITATIONS
73	Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment. <i>Infection</i> , 2011, 39, 375-378.	2.3	15
74	SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. <i>Annals of Oncology</i> , 2014, 25, 2339-2350.	0.6	15
75	Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP</i>53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	14
76	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 789-795.	0.6	13
77	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. <i>Leukemia Research</i> , 2014, 38, 1269-1277.	0.4	13
78	A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. <i>Transfusion</i> , 2014, 54, 2353-2360.	0.8	12
79	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	1.3	12
80	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. <i>Leukemia Research</i> , 2019, 81, 88-94.	0.4	11
81	Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 469-480.	0.7	9
82	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	0.8	9
83	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. <i>Blood</i> , 2021, 138, 2727-2730.	0.6	9
84	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8
85	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	2.5	8
86	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 459-466.	0.4	7
87	Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIDEM (Societ� Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di) <i>Tj ETQq1 1 0.784314 rgBT /Overlook</i>	0.5	7
88	Second versus first wave of COVID-19 in patients with MPN. <i>Leukemia</i> , 2022, 36, 897-900.	3.3	7
89	Clinical and Economic Issues in the Treatment of Advanced Breast Cancer with Bisphosphonates. <i>Drugs and Aging</i> , 2003, 20, 631-642.	1.3	6
90	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. <i>Cytotherapy</i> , 2014, 16, 101-110.	0.3	6

#	ARTICLE	IF	CITATIONS
91	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2076.	1.0	6
92	Value of innovation for hematologic malignancies. <i>Journal of Medical Economics</i> , 2016, 19, 487-489.	1.0	5
93	Cost-Effectiveness of Axicabtagene Ciloleucel for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Italy. <i>Blood</i> , 2018, 132, 4779-4779.	0.6	5
94	High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy. <i>Haematologica</i> , 2002, 87, 472-8.	1.7	5
95	Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 549-564.	0.7	3
96	Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 29-38.	0.7	3
97	Reduced Expression of CXCR4 on Circulating CD34+ Cells Is Associated with Hematopoietic Progenitor Cells (HPC) Mobilization in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). <i>Blood</i> , 2005, 106, 258-258.	0.6	3
98	Should I Transplant This Patient with Paroxysmal Nocturnal Hemoglobinuria? a Cost-Effectiveness Analysis of Eculizumab Versus Allogeneic Stem Cell Transplant. <i>Blood</i> , 2014, 124, 735-735.	0.6	3
99	Is Idelalisib Cost-Effective for Refractory/Relapsed Chronic Lymphocytic Leukemia? a Decision Analysis in the Second-Line Setting. <i>Blood</i> , 2015, 126, 3305-3305.	0.6	3
100	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
101	Screening for factor V Leiden mutation in pregnant women. <i>Lancet</i> , 2002, 360, 1518.	6.3	2
102	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. <i>Blood</i> , 2019, 134, 4170-4170.	0.6	2
103	Selecting α -Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm. <i>Blood</i> , 2019, 134, 972-972.	0.6	2
104	Cost-Effectiveness of Interim PET Response Adapted Therapy In ABVD-Treated, Advanced-Stage Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 1563-1563.	0.6	2
105	Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements: author reply. <i>Haematologica</i> , 2009, 94, 295-296.	1.7	2
106	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
107	Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies. <i>Journal of Clinical Medicine</i> , 2022, 11, 1826.	1.0	2
108	Drug-eluting stents: from evidence to policy. <i>Expert Review of Medical Devices</i> , 2004, 1, 49-63.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. <i>Leukemia</i> , 2020, 34, 1208-1209.	3.3	1
110	Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report. <i>European Journal of Haematology</i> , 2020, 105, 505-507.	1.1	1
111	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4279-4279.	0.6	1
112	Clonal Origin of Circulating Endothelial Progenitor Cells in Patients with Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2004, 104, 2427-2427.	0.6	1
113	Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Haematology International Journal</i> , 2017, 1, .	0.0	1
114	Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 263-272.	0.9	1
115	Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1868.	1.0	1
116	Regulation of HIF-1 $\hat{\pm}$ in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214.	0.2	0
117	Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e271.	0.2	0
118	Evaluation of Cytokines Mobilizing Hematopoietic Progenitor Cells in Patients with Myelofibrosis with Myeloid Metaplasia (MMM).. <i>Blood</i> , 2004, 104, 2434-2434.	0.6	0
119	Incidence and Clinical Profile of JAK2 V617F Mutation in Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2005, 106, 256-256.	0.6	0
120	^{99m} Tc-BW250/183 Bone Marrow Immunoscintigraphy Is Correlated to Clinical and Biologic Features of Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2005, 106, 4944-4944.	0.6	0
121	Revealing the Spectrum of Clinical Syndromes in Idiopathic Myelofibrosis by Cluster Analysis: Featuring "Indolent Myelofibrosis". <i>Blood</i> , 2006, 108, 2685-2685.	0.6	0
122	Reduced CD26 Dipeptidylpeptidase IV Membrane Expression and Activity of CD34+ Cells from Patients with Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2006, 108, 3617-3617.	0.6	0
123	Iron Supplementation Adjunct to Erythropoiesis Stimulating Agents Is Cost Saving for Chemotherapy-Related Anemia in the Era of Biosimilars. <i>Blood</i> , 2014, 124, 2165-2165.	0.6	0
124	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. <i>Blood</i> , 2015, 126, 2925-2925.	0.6	0
125	Identification of New BMP6 Pro-Peptide Mutations in Patients with Unexplained Iron-Overload. <i>Blood</i> , 2016, 128, 264-264.	0.6	0
126	HIF-1 $\hat{\pm}$ Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs. <i>Blood</i> , 2019, 134, 3044-3044.	0.6	0
128	Second <i><i>Versus</i></i> First Wave of COVID-19 in Patients with MPN. <i>Blood</i> , 2021, 138, 315-315.	0.6	0